Rein Therapeutics Inc.
RNTX
$0.92
-$0.03-2.98%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.51M | 10.90M | 11.42M | 9.96M | 12.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.55M | 21.93M | 23.77M | 24.35M | 26.52M |
| Operating Income | -21.55M | -21.93M | -23.77M | -24.35M | -26.52M |
| Income Before Tax | -50.92M | -50.58M | -60.43M | -60.70M | -62.82M |
| Income Tax Expenses | -712.00K | -712.00K | -1.54M | -1.54M | -1.54M |
| Earnings from Continuing Operations | -50.21 | -49.87 | -58.89 | -59.15 | -61.27 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.21M | -49.87M | -58.89M | -59.15M | -61.27M |
| EBIT | -21.55M | -21.93M | -23.77M | -24.35M | -26.52M |
| EBITDA | -21.55M | -21.91M | -23.75M | -24.33M | -26.50M |
| EPS Basic | -1.78 | -1.84 | -2.63 | -2.69 | -2.86 |
| Normalized Basic EPS | -0.51 | -0.55 | -0.62 | -0.66 | -0.77 |
| EPS Diluted | -1.78 | -1.84 | -2.63 | -2.69 | -2.86 |
| Normalized Diluted EPS | -0.51 | -0.55 | -0.62 | -0.66 | -0.77 |
| Average Basic Shares Outstanding | 110.17M | 101.73M | 94.16M | 89.46M | 85.18M |
| Average Diluted Shares Outstanding | 110.17M | 101.73M | 94.16M | 89.46M | 85.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |